% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Horne:132818,
author = {H. N. Horne and H. Oh and M. E. Sherman and M. Palakal and
S. M. Hewitt and M. K. Schmidt and R. L. Milne and D.
Hardisson and J. Benitez and C. Blomqvist and M. K. Bolla
and H. Brenner$^*$ and J. Chang-Claude$^*$ and R. Cora and
F. J. Couch and K. Cuk$^*$ and P. Devilee and D. F. Easton
and D. M. Eccles and U. Eilber$^*$ and J. M. Hartikainen and
P. Heikkilä and B. Holleczek and M. J. Hooning and M. Jones
and R. Keeman and A. Mannermaa and J. W. M. Martens and T.
A. Muranen and H. Nevanlinna and J. E. Olson and N. Orr and
J. I. A. Perez and P. D. P. Pharoah and K. J. Ruddy and
K.-U. Saum$^*$ and M. J. Schoemaker and C. Seynaeve and R.
Sironen and V. T. H. B. M. Smit and A. J. Swerdlow and M.
Tengström and A. S. Thomas and A. M. Timmermans and R. A.
E. M. Tollenaar and M. A. Troester and C. J. van Asperen and
C. H. M. van Deurzen and F. F. Van Leeuwen and L. J. Van't
Veer and M. García-Closas and J. D. Figueroa},
title = {{E}-cadherin breast tumor expression, risk factors and
survival: {P}ooled analysis of 5,933 cases from 12 studies
in the {B}reast {C}ancer {A}ssociation {C}onsortium.},
journal = {Scientific reports},
volume = {8},
number = {1},
issn = {2045-2322},
address = {London},
publisher = {Nature Publishing Group},
reportid = {DKFZ-2018-00462},
pages = {6574},
year = {2018},
abstract = {E-cadherin (CDH1) is a putative tumor suppressor gene
implicated in breast carcinogenesis. Yet, whether risk
factors or survival differ by E-cadherin tumor expression is
unclear. We evaluated E-cadherin tumor immunohistochemistry
expression using tissue microarrays of 5,933 female invasive
breast cancers from 12 studies from the Breast Cancer
Consortium. H-scores were calculated and case-case odds
ratios (OR) and $95\%$ confidence intervals (CIs) were
estimated using logistic regression. Survival analyses were
performed using Cox regression models. All analyses were
stratified by estrogen receptor (ER) status and histologic
subtype. E-cadherin low cases (N = 1191, $20\%)$ were
more frequently of lobular histology, low grade, >2 cm,
and HER2-negative. Loss of E-cadherin expression
(score < 100) was associated with menopausal hormone use
among ER-positive tumors (ever compared to never users,
OR = 1.24, $95\%$ CI = 0.97-1.59), which was
stronger when we evaluated complete loss of E-cadherin (i.e.
H-score = 0), OR = 1.57, $95\%$ CI = 1.06-2.33.
Breast cancer specific mortality was unrelated to E-cadherin
expression in multivariable models. E-cadherin low
expression is associated with lobular histology, tumor
characteristics and menopausal hormone use, with no evidence
of an association with breast cancer specific survival.
These data support loss of E-cadherin expression as an
important marker of tumor subtypes.},
cin = {C070 / G110 / C020 / L101},
ddc = {000},
cid = {I:(DE-He78)C070-20160331 / I:(DE-He78)G110-20160331 /
I:(DE-He78)C020-20160331 / I:(DE-He78)L101-20160331},
pnm = {313 - Cancer risk factors and prevention (POF3-313)},
pid = {G:(DE-HGF)POF3-313},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:29700408},
pmc = {pmc:PMC5920115},
doi = {10.1038/s41598-018-23733-4},
url = {https://inrepo02.dkfz.de/record/132818},
}